Jpmorgan Chase & CO Context Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 80 shares of CNTX stock, worth $110. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80
Previous 166
51.81%
Holding current value
$110
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CNTX
# of Institutions
43Shares Held
75.9MCall Options Held
0Put Options Held
0-
Bio Impact Capital LLC Cambridge, MA14.7MShares$20.3 Million1.9% of portfolio
-
Avidity Partners Management LP Dallas, TX7.48MShares$10.3 Million1.33% of portfolio
-
Nextech Invest Ag7.42MShares$10.2 Million1.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.42MShares$10.2 Million0.17% of portfolio
-
Nextech Invest, Ltd. Zurich, V87.42MShares$10.2 Million0.92% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $22M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...